NCT02925104 - A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 14, 2016

Primary Completion Date

May 16, 2018

Study Completion Date

May 16, 2018

Conditions

cMET Dysegulation Advanced Solid Tumors

Interventions

DRUG

INC280

Trial Locations (17)

2730

Novartis Investigative Site, Herlev

5020

Novartis Investigative Site, Salzburg

15706

Novartis Investigative Site, Santiago de Compostela

28040

Novartis Investigative Site, Madrid

29010

Novartis Investigative Site, Málaga

46202

Indiana University Simon Cancer Center SC, Indianapolis

50009

Novartis Investigative Site, Zaragoza

55131

Novartis Investigative Site, Mainz

01307

Novartis Investigative Site, Dresden

6500 HB

Novartis Investigative Site, Nijmegen

08041

Novartis Investigative Site, Barcelona

413 45

Novartis Investigative Site, Gothenburg

SE-221 85

Novartis Investigative Site, Lund

171 76

Novartis Investigative Site, Stockholm

SE-751 85

Novartis Investigative Site, Uppsala

W1G 6AD

Novartis Investigative Site, London

M20 4BX

Novartis Investigative Site, Manchester